Bristol-Myers Squibb will no longer make or market Tequin(gatifloxacin) but will not pull current supplies off the market.
Bristol-Myers Squibb will no longer make or market Tequin (gatifloxacin) but will not pull current supplies off the market. The company is returning its rights to Kyorin Pharmaceutical. In February, the FDA and BMS strengthened a warning against the use of Tequin by people with diabetes after reports of problems with high and low blood sugar associated with the drug. The watchdog group Public Citizen has petitioned the FDA to ban the drug, charging that it has caused deaths and hospitalizations.
To see more Hot off the Press news articles, click here click here.
To go to the Drug Topics homepage, click here.
Sulbactam-Durlobactam for Bacterial Pneumonia Gets FDA Approval
May 24th 2023The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
2 Clarke Drive
Cranbury, NJ 08512